OQS
ALLO icon

Occudo Quantitative Strategies’s Allogene Therapeutics ALLO Stock Holding History

Occudo Quantitative Strategies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-48,340
Closed -$522K – 933
2022
Q3 		$522K Sell
48,340
-20,250
-30% -$275K 0.04% 645
2022
Q2 		$782K Sell
68,590
-35,593
-34% -$316K 0.06% 465
2022
Q1 		$949K Buy
+104,183
New +$1.09M 0.08% 397
2021
Q1 		– Sell
-13,480
Closed -$340K – 733
2020
Q4 		$340K Buy
+13,480
New +$439K 0.11% 369

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Occudo Quantitative Strategies's ALLO Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 48,340 shares — an estimated $522K sold.

Occudo Quantitative Strategies first reported a position in ALLO in Q4 2020 and held it in 4 quarters. The position peaked at $949K in Q1 2022. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 48,340 Allogene Therapeutics shares in Q4 2022, an estimated $522K.
  • Occudo Quantitative Strategies first reported a position in Allogene Therapeutics in Q4 2020 and held it in 4 quarters.
  • Occudo Quantitative Strategies's Allogene Therapeutics position peaked at $949K in Q1 2022.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.